Nav: Home

Clinical efficacy & future development of continuous glucose monitoring highlighted in DTT

June 07, 2017

New Rochelle, NY, June 7, 2017--A growing body of data from clinical studies of continuous glucose monitoring (CGM) in type 1 diabetes supports the value of CGM for reducing variability in blood glucose levels and the risks of both hypo- and hyperglycemia, and for improving patient quality of life compared to self-monitoring of blood glucose (SMBG). A review of recent CGM trials and the impact of CGM accuracy on the future of automated insulin delivery systems are the focus of two in a series of articles published as a special supplement to Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The supplement is available open access on the DTT website.

In the article entitled "Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes," David Rodbard, MD, Biomedical Informatics Consultants, Potomac, MD, concluded that CGM, as well as flash glucose monitoring, has been shown to be safe and effective, with the recent regulatory approval of certain CGM devices for nonadjunctive use to guide insulin dose adjustment representing a major advance.

In the "Future of Automated Insulin Delivery Systems," Jessica Castle, MD, Oregon Health & Science University, Portland, J. Hans DeVries, MD, University of Amsterdam, The Netherlands, and Boris Kovatchev, PhD, University of Virginia, Charlottesville, discuss how CGM has enabled the automation of insulin delivery. The authors describe the rapid progress in the development of automated insulin delivery systems, the novel features and advantages they may offer for improving glycemic control, and the critical role that highly accurate CGM will play in the safe and effective use of these systems.

In the Editorial entitled "The Future of Continuous Glucose," DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora) states: "Continuous glucose monitors have come a long way with significant improvement in accuracy and MARD of <10%." Just like all patients with new-onset T1D [type 1 diabetes] get an SMBG meter today, we hope in the very near future, all patients with new-onset T1D will receive CGM."

Research reported in this publication was supported by the National Institutes of Health under Award Number 1DP3DK101044-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
-end-
This supplement was supported by an educational grant from Dexcom. Dexcom G5 is the first and currently only CGM approved for nonadjunctive use in the US.

About the Journal

Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT)website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD

The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world's leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc./Genetic Engineering News

Related Blood Glucose Articles:

Small rises in blood glucose trigger big changes in insulin-producing cells
This study provides a wealth of new data showing how beta cells behave at slightly raised levels of blood glucose -- still within the pre-diabetes range.
High blood glucose levels may explain why some flu patients experience severe symptoms
Influenza A (a highly contagious virus that causes annual flu epidemics worldwide) may trigger an inflammatory 'cytokine storm' -- an excessive immune response that can lead to hospitalization or even death -- by increasing glucose metabolism, according to a new study.
Loss of gland in eyelids may be a biomarker for elevated blood glucose in diabetes
In patients with diabetes, loss of the gland that helps lubricate the eye may be a sign of elevated blood glucose levels, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting.
Medtronic MiniMed 670G insulin pump allows 'excellent' blood glucose control
Patients with type 1 diabetes who use Medtronic's MiniMedTM 670G insulin pump system are able to maintain blood glucose levels in the targeted range over 71% of the time, according to a study that analyzed some 6 million days of real-world data.
'Revita' improves blood glucose levels, liver metabolic health in type 2 diabetes
Patients with poorly controlled type 2 diabetes who underwent a novel, minimally invasive, endoscopic procedure called Revita® duodenal mucosal resurfacing (DMR) had significantly improved blood glucose (sugar) levels, liver insulin sensitivity, and other metabolic measures three months later, according to new data from the REVITA-2 study.
Artificial pancreas system better controls blood glucose levels than current technology
Study based at the Icahn School of Medicine at Mount Sinai and other centers finds new system has safety, efficacy benefits for people with type 1 diabetes
New study sheds light on how blood vessel damage from high glucose concentrations unfolds
A mechanism in the cells that line our blood vessels that helps them to process glucose becomes uncontrolled in diabetes, and could be linked to the formation of blood clots and inflammation according to researchers from the University of Warwick.
Blood pressure and glucose control may prevent common arrhythmia
Blood-pressure and glucose control may be effective in preventing heart block, a common form of arrhythmia, and the subsequent need for a pacemaker, according to a study by researchers at UC San Francisco.
Time-restricted eating shows benefits for blood glucose
By restricting the time period during which they could eat, researchers have seen promising results for controlling blood glucose levels in men at risk of type 2 diabetes.
Leaving 2-hour gap between dinner and bedtime may not affect blood glucose
Leaving a two-hour gap between the last meal of the day and bedtime doesn't seem to be associated with any discernible difference in blood glucose levels among healthy adults over the long term, suggests Japanese research published in the online journal BMJ Nutrition, Prevention & Health.
More Blood Glucose News and Blood Glucose Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.